Clinical Trial Update: Acalabrutinib Plus Rituximab for the Treatment of Elderly or Low- to Intermediate-Risk Younger Untreated Mantle Cell Lymphoma [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is evaluating the combination of acalabrutinib and rituximab in elderly or low- to intermediate-risk younger patients with untreated Ma…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mantle Cell Lymphoma

Drugs mentioned

• CALQUENCE (ACALABRUTINIB)
• Rituxan (rituximab)

Snippet

Sponsor: Sun Yat-sen University | Conditions: Mantle Cell Lymphoma (MCL) | Phase 2 | Status: RECRUITING